Publications

onc212

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

Oncotarget 2017 PMID: 29137221

Lev A, Lulla AR, Wagner J, et al.

onc201

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget

Oncotarget. 2017 PMID: 29108308

Arrillaga-Romany I, Chi AS, Allen JE, et al.

imipridones

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212

Cell Cycle. 2017 PMID: 28489985

Wagner J, Kline CL, Ralff MD, et al.

onc201

First-in-Human clinical trial of oral ONC201 in patients with refractory solid tumors

Clin Cancer Res. 2017 PMID: 28331050

Stein MN, Bertino JR, Kaufman HL, et al.

onc201

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

Sci Signal. 2016 PMID: 26884599

Ishizawa J, Kojima K, Chachad D, et al.

onc201

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases

Sci Signal. 2016 PMID: 26884600

Kline CLB, Van den Heuvel APJ, Allen JE, et al.

onc201

Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects

Science Translational Medicine 2013, PMID: 23390247

Allen JE, Krigsfeld G, Mayes PA, et al.